Krazati — Total Revenues
Bristol-Myers Squibb Krazati — Total Revenues increased by 10.4% to $53.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 55.9%, from $34.00M to $53.00M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration, strong physician adoption, or expanded clinical indications for the drug, while a decrease may signal competitive pressure, patent challenges, or declining demand.
Detailed definition
This metric represents the total net sales generated from the commercialization of Krazati, a targeted therapy for speci...
Peer comparison
Comparable to revenue metrics for specific high-growth oncology assets or targeted therapies at other major pharmaceutical companies, often benchmarked against peak sales expectations.
bmy_segment_krazati_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $21.00M | $32.00M | $34.00M | $39.00M | $48.00M | $48.00M | $53.00M |
| QoQ Change | — | — | — | — | — | — | — | — | — | +52.4% | +6.3% | +14.7% | +23.1% | +0.0% | +10.4% |
| YoY Change | — | — | — | — | — | — | — | — | — | — | — | — | +128.6% | +50.0% | +55.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's krazati — total revenues?
- Bristol-Myers Squibb (BMY) reported krazati — total revenues of $53.00M in Q3 2025.
- How has Bristol-Myers Squibb's krazati — total revenues changed year-over-year?
- Bristol-Myers Squibb's krazati — total revenues increased by 55.9% year-over-year, from $34.00M to $53.00M.
- What does krazati — total revenues mean?
- The total revenue generated from the sales of the drug Krazati.